The clinical relevance of the combination of PDPK1 and MEK inhibitors was also demonstrated in the NRAS-mutated xenograft model, indicating the efficiency of the combinatorial strategy for the treatment of melanoma patients with NRAS mutation [172,174]. This evidence concerns the gene MAP2K7 and melanoma.